Laronidase [usan:inn]

Base Information

• Chemical Name: Laronidase [usan:inn]
• CAS No.: 210589-09-6
• Molecular Weight: 0.00000

Synonyms:Laronidase (genetical recombination);Human Recombinant alpha-L-iduronidase;Aldurazyme;alpha-L-Iduronidase;Laronidase;Iduronidase,alpha-L-(8-histidine) (human). Molecular weight is approximately 82,000 daltons;alpha-L-Idosiduronase;EC 3.2.1.76;Iduronidase, alpha-L-(8-histidine) (human);

Chemical Property of Laronidase [usan:inn]

Chemical Property:

• PSA: 0.00000
• LogP: 0.00000
• Storage Temp.: -20°C

Purity/Quality:

99% ^*data from raw suppliers

IDUA ^*data from reagent suppliers

Safty Information:

• Pictogram(s):  
• Hazard Codes: 

MSDS Files:

Useful:

• Description: Mucopolysaccharidosis I (MPS I) is a rare genetic lysosomal storage disease caused by the deficiency of a-L-iduronidase, an enzyme required for the catabolism of dermatan sulfate and heparin sulfate. The deficiency blocks the degradation of these mucopolysaccharides, which accumulate in a variety of tissues including liver, spleen, heart and connective tissues. The clinical manifestations of MPS I can include progressive developmental delay, airways obstruction, hepatosplenomegaly, severe joint restriction and cardiovascular disease. There are three subtypes of MPS I depending on its clinical severity: Hurler’s syndrome (severe), Hurler-Scheie syndrome (moderate), and Scheie syndrome (mild). Among the existing therapies, bone marrow transplantation has been the only effective option for Hurler’s syndrome. Laronidase was launched as an enzyme replacement therapy for the treatment of patients with Hurler and Hurler-Scheie syndromes and patients with the Scheie syndrome who have moderate to severe symptoms. It is a recombinant form of the human a-L-iduronidase produced by overexpression in a Chinese hamster ovary cell line. The recommended dosage regimen of laronidase is 0.58 mg/kg of body weight administered once weekly as an intravenous infusion. The efficacy of laronidase was demonstrated in a 26-week, double-blind, placebo-controlled clinical trial by measuring improvement in pulmonary function and endurance. The laronidase-treated patients showed a mean increase of 4.0% in predicted forced vital capacity (FVC) and a mean increase of 38.0 m in the distance walked in 6 min as compared with placebo-treated patients. Reductions in liver size and in urinary glycosaminoglycan excretion were also observed. The most common adverse events associated with laronidase were upper respiratory tract infection, rash and injection site reaction.
• Uses: Enzyme replacement in Mucopolysaccharidosis I (MPS I).

Post a RFQ

Cas No.:

Product Name:

Quantity:

Please select Metric Ton KG G Pound L ML

Email:

Company name:

Valid Period:

Detailed Requirements:

• Sample
• MOQ
• GMP
• FDA
• Price
  FOB CIF CFR EXW
• Urgent purchase

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

Remove

Submit

1

What can I do for you?
Get Best Price

Get Best Price for 210589-09-6 Laronidase [usan:inn]

Send

Send

Metric Ton KG G Pound L ML

Send

Send